Melanoma Research Alliance

Stephanie Kauffman, chief executive officer of the Melanoma Research Alliance, discussed funding strategy, early career researcher support, and melanoma prevention in a recent Dermatology Times interview.

Test your knowledge of Tudriqev’s accelerated approval, clinical activity, administration, and ongoing confirmatory research.

Stephanie Kauffman, CEO of the Melanoma Research Alliance, discussed the organization's research priorities as it approaches 20 years of advancing melanoma research.

Joan Levy, PhD, chief science officer at the Melanoma Research Alliance, discussed the significance of Tudriqev's accelerated approval for patients with anti-PD-1-refractory melanoma.

MRA commits a record $18.4M to global melanoma research, boosting rare-subtype collaboration, biorepositories, biomarkers, and next-gen therapies to combat rising cases.

A JAMA Dermatology study found that US veterans with documented Agent Orange exposure had approximately 30% higher odds of developing acral melanoma compared with unexposed veterans.

Marc Hurlbert, PhD, discusses how the Melanoma Research Alliance works with dermatology clinicians to provide fundings and resources for melanoma research.

The Melanoma Research Alliance provides funding to support investigators in preventing, detecting, and treating melanoma.